In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s Innovation Catalyst Sets Out Cardiology And Biomarker Opportunities

Executive Summary

Draft topics for funding in the next two rounds of the EU’s Innovative Health Initiative present more opportunities for the medtech sector to combine forces in cross-sector R&I.

You may also be interested in...



How Manufacturers Of Innovative Devices For Stroke Patients Could Benefit From EU Funding

The EU Innovative Health Initiative will soon open its doors for the latest round of applicants, with up to €40 million ($44m) available in funding for each project. But who is eligible to apply for the scheme, and where do the key opportunities for medtech lie?

IHI: Europe’s Research And Innovation Project Is A Watchtower For Medtechs

April will see the first call for proposals under the Innovative Health Initiative, a patient-centric, demand-led project that is about to come to life for technology innovators after 30 months of negotiations and preparations by European health care industry associations and the European Commission.

European Commission Launches Data Collection Initiative To Avoid Medtech Product Shortfalls

There is a much-acknowledged urgency to ensure medtech products are certified as fast as possible, with fears persisting that delays will result in notified body bottlenecks and product shortages.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel